Scarica l'app Stockscreener
1.8191
10.00%
0.1691
Alx Oncology Holdings Inc Borsa (ALXO) Ultime notizie
ALX Oncology Strengthens Leadership with Key Appointments - TipRanks
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors - The Manila Times
ALX Oncology Announces Further Additions to Leadership Team - GlobeNewswire
ALX Oncology Strengthens Leadership with Strategic CFO and Board Appointments for Clinical Push - StockTitan
ALX Oncology to Host Virtual Company Event Highlighting - GlobeNewswire
ALX Oncology to Present Crucial Evorpacept Cancer Trial Data at ASCO GI Symposium - StockTitan
ALX Oncology launches new equity incentive plan - MSN
ALX Oncology launches new equity incentive plan By Investing.com - Investing.com South Africa
ALX Oncology Adopts 2025 Inducement Equity Plan - TipRanks
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Down 9.4% in December - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Jane Street Group LLC Trims Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Barclays PLC Buys 42,185 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
3 US Penny Stocks With Market Caps Under $100M To Watch - Yahoo Finance
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
State Street Corp Trims Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Alx oncology interim CFO Pinto sells $2,253 in stock By Investing.com - Investing.com Australia
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 10,796 Shares - MarketBeat
Alx Oncology president sells $17,059 in stock By Investing.com - Investing.com Nigeria
Alx Oncology president sells $17,059 in stock - Investing.com
Alx oncology interim CFO Pinto sells $2,253 in stock - Investing.com
Bicara’s era? Merus, ALX also active in head and neck cancer - BioWorld Online
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Up 17.0% in December - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Large Increase in Short Interest - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Jefferies Financial Group Downgrades ALX Oncology (NASDAQ:ALXO) to Hold - Defense World
ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
ALX Oncology’s (ALXO) “Buy” Rating Reiterated at HC Wainwright - Defense World
Alx Oncology Holdings Inc (ALXO) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
ALX Oncology falls as Jefferies cuts on lead cancer drug - MSN
ALX Oncology stock falls on Jefferies downgrade (ALXO:NASDAQ) - Seeking Alpha
Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' - Investing.com Canada
ALX Oncology (NASDAQ:ALXO) Rating Lowered to Hold at Jefferies Financial Group - MarketBeat
ALX Oncology shares target steady, hold rating on positive clinical results - Investing.com Canada
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines - Baystreet.ca
ALX Oncology (NASDAQ:ALXO) Earns "Overweight" Rating from Cantor Fitzgerald - MarketBeat
HC Wainwright Reiterates Buy Rating for ALX Oncology (NASDAQ:ALXO) - MarketBeat
ALX Oncology to Present Updated Results from Phase 2 - GlobeNewswire
ALX Oncology to Present Key Phase 2 Gastric Cancer Trial Data at ASCO GI 2025 Symposium - StockTitan
Verition Fund Management LLC Acquires 100,454 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Highlights Promising Trial Results - MSN
ALX Oncology to Host Webcast on December 17 Featuring Phase 1b/2 Trial Data for Evorpacept in Metastatic Breast Cancer - Nasdaq
0.81%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):